Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen -
- Company anticipates topline, interim data for RSV lead program IVX-121 in 2Q 2022 -
- Announced emerging program in flu, as part of strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults -
- Reported topline Phase 1/2 results for IVX-411 Against SARS-CoV-2 -
https://finance.yahoo.com/news/icosavax-reports-fourth-quarter-full-201500423.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.